COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02048722
Recruitment Status : Active, not recruiting
First Posted : January 29, 2014
Last Update Posted : February 18, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

Brief Summary:
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers.

Condition or disease Intervention/treatment Phase
Adult Angiosarcoma Recurrent Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Drug: regorafenib Phase 2

Detailed Description:


I. To define the progression-free survival (PFS) at 4 months with daily oral regorafenib (160 mg) in previously treated locally advanced/metastatic angiosarcoma patients


I. Progression-free rate at 3 and 6 months. II. Progression-free survival. III. Overall survival (up to 5 years). IV. Response rate (by Response Evaluation Criteria in Solid Tumors [RECIST] version [v] 1.1).

V. Rate and duration of tumor control (complete response [CR] + partial response [PR] + stable disease [SD]).

VI. Safety/tolerability of regorafenib.


Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Study Start Date : March 2014
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Regorafenib

Arm Intervention/treatment
Experimental: Treatment (regorafenib)
Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: regorafenib
Given PO
Other Names:
  • BAY 73-4506
  • multikinase inhibitor BAY 73-4506
  • Stivarga

Primary Outcome Measures :
  1. Progression-Free Survival (PFS) at 4 months [ Time Frame: At 4 months (of treatment) ]
    PFS will be evaluated at 4 months and will be defined as the absence of disease progression.

Secondary Outcome Measures :
  1. Progression-Free Rate (PFR) at 3 and 6 months [ Time Frame: Assessed at 3 months and 6 months ]
    Patients will be evaluated at 3 and 6 months for the absence of disease progression, this data will be used to calculate the PFR.

  2. Progression-free survival (PFS) [ Time Frame: The duration of time from start of treatment until time of progression, up to 5 years ]
    PFS will be measured as the duration of time from the start of treatment until the time of disease progression, patients will be followed-up with for up to 5 years.

  3. Overall survival [ Time Frame: From start of treatment up to 5 years ]
    Once off-treatment, patients will be followed for overall survival for up to 5 years.

  4. Response rate (of tumor to treatment) [ Time Frame: At baseline and after every 2 cycles, up to 7 years ]
    Imaging (such as a CT scan) will be done at baseline (within 4 weeks before the first dose) then after every 2 cycles while on treatment for tumor response evaluation.

  5. Rate and duration of tumor control [ Time Frame: At baseline and after every 2 cycles, up to 7 years ]
    Imaging will be used at baseline then after every 2 cycles while on treatment to measure tumor size and response to treatment, the data collected from all patients on study will be used to calculate the rate and duration of tumor control.

  6. Number of Grade 1, 2, 3, 4, and 5 Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) [ Time Frame: Measured at baseline & at each cycle, for up to 7 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Life expectancy of at least 4 months
  • Histologically confirmed angiosarcoma
  • Tumor deemed unresectable or metastatic
  • Measurable disease per RECIST v 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Progressive disease under last palliative therapy with a history of prior ifosfamide, doxorubicin or taxane therapy for angiosarcoma; up to 4 prior therapies are allowed
  • All acute toxic effects of any prior treatment have resolved to grade 1 or less (by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v 4.0) at the time of registration; NOTE: Exceptions to this criterion will include alopecia and fatigue
  • Total bilirubin =< 1.5 x the upper limits of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
  • Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
  • Lipase =< 1.5 x the ULN
  • Serum creatinine =< 1.5 x the ULN
  • International normalized ratio (INR)/partial thromboplastin time (PTT) < 1.5 x ULN
  • Platelet count > 100000/mm^3
  • Hemoglobin > 9 g/dL
  • Absolute neutrophil count > 1500/mm^3
  • If baseline urine protein creatinine (UPC) >= 1, a 24-hour urine protein must be assessed; patients must have a 24-hour urine protein value < grade 3 (> 3.5 g/24 hours) to be eligible
  • NOTE: Blood transfusion to meet the above criteria will not be allowed; NOTE: Patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
  • Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as age >= 50 years and no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
  • Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at registration until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator
  • Subject must be able to swallow and retain oral medication
  • Subjects must be able to understand and be willing to sign the written informed consent form; a signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure

Exclusion Criteria:

  • Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
  • Active or clinically significant cardiac disease including:

    • Congestive heart failure - New York Heart Association > class II
    • Active coronary artery disease
    • Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
    • Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before registration, or myocardial infarction within 6 months before registration
  • Evidence or history of bleeding diathesis or coagulopathy
  • Any hemorrhage or bleeding event grade 3 within 4 weeks prior to registration
  • Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent
  • Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma; NOTE: Exceptions include cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed; all treatments must have been completed at least 3 years prior to registration
  • Patients with pheochromocytoma
  • Patients with severe hepatic impairment (Child-Pugh class C)
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
  • Ongoing infection > grade 2
  • Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors
  • Presence of a non-healing wound, non-healing ulcer, or bone fracture
  • Renal failure requiring hemo-or peritoneal dialysis
  • Dehydration > grade 1
  • Interstitial lung disease with ongoing signs and symptoms at the time of registration
  • Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)
  • History of organ allograft (including corneal transplant)
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
  • Any malabsorption condition
  • Evidence of abdominal fistula, gastrointestinal (GI) perforation or intraabdominal abscess
  • Women who are pregnant or breast-feeding
  • Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)
  • Prior use of regorafenib
  • Prior use of sorafenib
  • Use of cytotoxic chemotherapy within 21 days of registration
  • Use of targeted therapy within two half-lives of registration
  • Radiation directed at target lesion within 28 days of registration
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration
  • Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; NOTE: Prophylactic anticoagulation as described below is allowed:

    • Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes
    • Low dose aspirin (=< 100 mg daily)
    • Prophylactic doses of heparin
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02048722

Layout table for location information
United States, California
Sarcoma Oncology Center
Santa Monica, California, United States, 90403
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52246
United States, Minnesota
University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota, United States, 55455
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University-St. Louis
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Northwestern University
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Mark Agulnik, M.D. Northwestern University
Layout table for additonal information
Responsible Party: Northwestern University Identifier: NCT02048722    
Other Study ID Numbers: NU 13S02
NCI-2013-02278 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
STU00087654 ( Other Identifier: Northwestern University IRB# )
NU 13S02 ( Other Identifier: Northwestern University )
P30CA060553 ( U.S. NIH Grant/Contract )
First Posted: January 29, 2014    Key Record Dates
Last Update Posted: February 18, 2020
Last Verified: February 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue